Project Grant R21DA063914
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $194K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This federal Project Grant award of $233,250 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to evaluate the prevalence of the illicit drug adulterant xylazine and investigate the etiology of xylazine-related invasive infections. The key products/services to be delivered through this 2-year project include: Active surveillance of the local illicit drug supply in St. Louis, Missouri, using mass spectrometry and microbiologic...
- This $197,024 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports two multi-methods studies to characterize the impact of the veterinary tranquilizer xylazine on people who use drugs (PWUD) in North Carolina and Maine. The first study in North Carolina aims to describe PWUD's perceptions and experiences with xylazine and related complications, such as overdoses and skin ulcers, through surveys...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct research on the effects of xylazine and opioids on prefrontal cortex inhibitory transmission. The research aims to understand xylazine's cell signaling profiles and interactions with opioids at the circuit level, as xylazine is becoming highly prevalent in illicit opioid supplies and poses an...
- This $387,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research by Mercer University to investigate the molecular pharmacology of the drug xylazine and its effects on adrenoceptors. The research aims to assess xylazine's binding affinity and functional profiles at different adrenoceptor subtypes expressed in vascular smooth muscle cells, as well as directly test the hypothesis that...
- The Project Grant award of $231,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the University of Rochester to determine if the drug xylazine and its metabolites act as agonists or positive allosteric modulators at the mu and kappa opioid receptors. Additional studies will investigate whether xylazine and its metabolites are agonists, antagonists, or inverse agonists at the sigma 1 and sigma 2 receptors....
- This Project Grant award, valued at $506,000.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Scripps Research Institute to develop monoclonal antibodies that can block the mechanism of action and adverse effects of the drug xylazine. Xylazine has emerged as an adulterant in illicit drug mixtures, contributing to overdose deaths, and this research aims to create novel therapeutic...
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- This Project Grant award of $554,778 from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is funded under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports preclinical proof-of-concept studies to confirm the ability of the respiratory stimulant drug Etimizol to reverse respiratory depression induced by the combination of the opioid fentanyl and the veterinary sedative xylazine. This is in response to the growing threat of...
- The U.S. Department of Health and Human Services' National Institutes of Health (NIH) awarded a $189,672 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Davidson College in North Carolina. The grant, awarded on August 15, 2025, supports a study titled "Fentanyl and Xylazine Interactions: Toxicity Produced by 'Tranq-Dope'." The project aims to quantify the interactions between fentanyl (a mu opioid receptor agonist) and xylazine (an alpha 2 adrenergic...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,460.00 to Brown University to develop a rule-based natural language processing (NLP) algorithm to identify patients exposed to fentanyl adulterated or associated with the veterinary sedative xylazine (FAAX). The key products and services to be delivered include: 1) Conducting 20-24 in-depth interviews with people who use drugs in Rhode...